Regenxbio rises on early data from muscle disorder gene therapy trial
05/06/2025 13:35
** Shares of gene therapy developer Regenxbio RGNX.O up 2.7% at $10.35 premarket ** RGNX says its experimental gene therapy, RGX-202, for the treatment of Duchenne muscular dystrophy (DMD) was safe with no serious adverse events observed in early-stage study ** DMD causes skeletal and heart muscle weakness that quickly worsens with time ** Company says study data is expected to support regulatory pathway of accelerated approval in mid-2026 ** Expects to share further study data in H1 2026 ** Up to last close, RGNX up 30.4% YTD (Reporting by Siddhi Mahatole) ((siddhi.mahatole@thomsonreuters.com))